Compare
Amarin Corp PLC vs Puma Biotechnology, Inc. vs Akebia Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.
| Latest fiscal year | Amarin Corp PLC AMRN | Puma Biotechnology, Inc. PBYI | Akebia Therapeutics, Inc. AKBA | Rhythm Pharmaceuticals, Inc. RYTM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $213.65M | $228.37M | $236.20M | $189.76M |
| Revenue growth (YoY) | -6.5% | -0.9% | +47.5% | +45.8% |
| Gross margin | 56.6% | 74.5% (computed) | 83.3% (computed) | 89.7% (computed) |
| Operating margin | -23.5% | 16.3% | 9.9% | -101.2% |
| Net margin | -18.2% | 13.6% | -2.3% | -103.6% |
| Net income | -$38.80M | $31.11M | -$5.34M | -$196.54M |
| EPS (Diluted) | -$0.09 | $0.61 | -$0.02 | -$3.11 |
| Operating cash flow | $6.73M | $41.80M | $67.99M | -$115.67M |
| Free cash flow | n/a | $41.73M | $67.70M | -$116.63M |
| Cash & equivalents | $134.66M | $29.64M | $184.84M | $54.30M |
| Total assets | $670.77M | $216.30M | $376.56M | $480.20M |
| Total liabilities | $211.49M | $85.96M | $343.95M | $210.17M |
| Shareholders' equity | $459.28M | $130.34M | $32.61M | $139.07M |
| Return on year-end equity | -8.4% | 23.9% | -16.4% | -141.3% |
| Shares outstanding | 416.21M | 50.41M | 265.42M | 67.21M |
Revenue, most recent five fiscal years
| Fiscal year | Amarin Corp PLC | Puma Biotechnology, Inc. | Akebia Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $213.65M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $236.20M Ended 2025-12-31 | $189.76M Ended 2025-12-31 |
| 1 year earlier | $228.61M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $160.18M Ended 2024-12-31 | $130.13M Ended 2024-12-31 |
| 2 years earlier | $306.91M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $194.62M Ended 2023-12-31 | $77.43M Ended 2023-12-31 |
| 3 years earlier | $369.19M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $292.48M Ended 2022-12-31 | $23.64M Ended 2022-12-31 |
| 4 years earlier | $583.19M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $211.65M Ended 2021-12-31 | $3.15M Ended 2021-12-31 |